Coming off banner years for health services deals in both 2021 and 2022, volumes have remained resilient through May 15, 2023, despite multiple headwinds — including higher interest rates, increased antitrust regulatory review concerns, elevated (though softening) valuations, and general recessionary fears and macroeconomic concerns, notes PwC.
PwC continues to remain optimistic about the health services deals outlook for the remainder of 2023, with corporate and private equity players alike holding large levels of capital that needs to be deployed, and sector dynamics driving a need for health services companies to adapt and reinvent themselves. Read more.
